NASDAQ$AONC
American Oncology Network In · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
AONC Q1 2024 — $362K revenue, 1.00 EPS
United States Private Securities Litigation Reform Act of 1995, including statements about the financial condition, results of operations, earnings outlook and prospects of American Oncology Network, . American Oncology Network In reported Q1 2024 results. Diluted EPS came in at $1.00. Net income of $25K. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $362K.
- Diluted EPS: $1.00.
- Net income: $25K.
Headline financials
Revenue & EPS history
American Oncology Network · Revenue · Quarterly
$364M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 1 quarterly earnings reports
-1.0%
Avg return
Earnings day
-7.8%
Avg return
5 days after
-4.0%
Avg return
30 days after
40%
2 / 5 earnings
Positive
+3.3%
Q1 2025
Best reaction
-4.4%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2025 | +3.3% | -0.8% | -11.7% | |
| Q3 2024 | +1.1% | -14.8% | +3.7% | |
| Q2 2024 | -0.9% | — | — | |
| Q1 2024 | — | — | — | |
| Q4 2023 | -4.4% | — | — | |
| Q3 2023 | -4.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro